Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 8, 2009

Aileron Scores $40M in Financing to Advance Preclinical Stapled Peptides

Aileron Scores $40M in Financing to Advance Preclinical Stapled Peptides

Aileron has gained $40M in Series D financing from Big Pharma and others

  • Aileron Therapeutics completed a series D financing deal worth $40 million. The company says that the funding will help move the lead candidate from its stapled peptides program into clinical trials next year. It will also be used to expand the platform in oncology, immunity and inflammation, metabolic disorders, and infectious diseases.

    Glaxosmithkline's investment wing, SR One, and Excel Medical fund co-led the financing round. Contributions also came from Lilly Ventures, Roche Venture Fund, Apple Tree Partners, and Novartis Venture Fund. Previous rounds of financing netted the company $20 million.

    "We believe that stapled peptides could represent a 'fourth estate' in therapeutics, emerging as a major class akin to small molecules, antibodies, and vaccines," says Michael Diem, M.D., partner at SR One.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »